Roche Holding AG Total Non-Cash Items 2010-2024 | RHHBY
Roche Holding AG annual/quarterly total non-cash items history and growth rate from 2010 to 2024. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
- Roche Holding AG total non-cash items for the quarter ending December 31, 2024 were $3.888B, a 97.61% increase year-over-year.
- Roche Holding AG total non-cash items for the twelve months ending December 31, 2024 were $13.722B, a 2.76% decline year-over-year.
- Roche Holding AG annual total non-cash items for 2024 were $17.203B, a 50.54% increase from 2023.
- Roche Holding AG annual total non-cash items for 2023 were $11.428B, a 12.75% decline from 2022.
- Roche Holding AG annual total non-cash items for 2022 were $13.098B, a 2.62% increase from 2021.
Roche Holding AG Annual Total Non-Cash Items
(Millions of US $) |
| 2024 |
$17,203 |
| 2023 |
$11,428 |
| 2022 |
$13,098 |
| 2021 |
$12,763 |
| 2020 |
$11,248 |
| 2019 |
$12,767 |
| 2018 |
$13,863 |
| 2017 |
$13,650 |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$2,681 |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$244.530B |
$68.726B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
